Besides, recent efforts have focused on developing targeted therapies for pancreatic cancer, including drugs that target specific molecular alterations like the KRAS oncogene, which is frequently mutated in pancreatic cancer (9–11). The gene discussed is KRAS; the disease is pancreatic neoplasm.